Developing of comorbidities associated with impaired immune and cardiovascular function in patients with chronic kidney disease is impossible. That is why the study of potential indicators of the development of pathological conditions of the cardiovascular system in patients with chronic kidney disease is relevant and necessary. The purpose of the work was to study the qualitative state of lipoproteins, enzyme activity, in patients with chronic kidney disease. Material and methods. To achieve this goal, the activity of paraoxonase-1 and serum myeloperoxidase was determined in 36 patients with chronic kidney disease. The activity of paraoxonase-1 was determined spectrophotometrically by the number of phenolic complexes formed using phenylacetate; myeloperoxidase activity was researched by reaction with hydrogen peroxide in the presence and without its specific inhibitor (gamma-aminobenzoic acid). Results and discussion. According to the results of our studies, the activity of paraoxonase-1 in the reference group of conditionally healthy individuals was 6.57 kU / l. In the group of patients with stage I-II of chronic kidney disease enzyme activity decreased by 30% (4,58 kU / l) and in the group of patients with stage V of chronic kidney disease it decreased by 46% (3,55 kU / l) compared with the reference group. Data analysis by the Kruskal-Wallis test (P <0.05) confirmed the difference between the groups. Dunn’s test indicated that there was a difference between control and both groups of patients (P <0.05). Myeloperoxidase activity in patients in group 1 was almost halved to an average of 0.12 conventional units / l, and in patients in group 2, on the contrary, increased 1.5 times (up to 0.37 conventional units / l). Data analysis using the Kruskal-Wallis (P <0.05) and Dunn’s tests established the difference between control and patient groups (P <0.05). Conclusion. The decreased paraoxonase-1 activity was observed in both groups of patients with chronic kidney disease compared with controls. Increased myeloperoxidase activity was observed in patients with stage V of chronic kidney disease, and a decrease in patients with stage I of chronic kidney disease. Thus, the activity of enzymes, in the composition of high-density lipoproteins, reflected their functional status and indicated pathological changes in the body, more pronounced in patients with stage V of chronic kidney disease. We suggest using the activity of paraoxonase-1 and myeloperoxidase as potential markers to prevent the development of complications of cardiovascular disease in patients with chronic kidney disease.
Full text: PDF (Ukr) 254K